Investment Thesis
Avalon GloboCare is in severe financial distress with negative stockholders' equity of -4.5M, indicating liabilities exceed assets. The company is unprofitable with massive operating losses (-5.8M on 1.1M revenue) and negative free cash flow (-4.4M), while maintaining critically low liquidity (0.15x current ratio) with only 333.9K in cash. Without immediate capital infusion or dramatic operational turnaround, the company faces insolvency risk.
ALBT Strengths
- Modest revenue growth of 6.2% YoY shows some demand for services
- Long-term debt remains relatively low at 67.4K
- Recent EPS improvement of 64.5% YoY indicates some margin stabilization from prior periods
ALBT Risks
- Negative stockholders' equity of -4.5M indicates technical insolvency and shareholder capital depletion
- Severely negative operating margins (-549.5%) with operating losses far exceeding revenue
- Critical liquidity crisis: current ratio of 0.15x means 0.15 dollars of current assets per dollar of current liabilities
- Persistent negative operating cash flow of -4.4M cannot be sustained with only 333.9K cash reserves
- Gross margin of only 10.4% provides minimal cushion to cover operating expenses
- No viable path to profitability visible in current operational structure
Key Metrics to Watch
- Monthly cash burn rate and runway to capital depletion
- Operating expense reduction progress and path to positive operating income
- Revenue growth sustainability and gross margin expansion
- Emergency capital raises, debt restructuring, or strategic partnerships
- Working capital management and accounts payable obligations
ALBT Financial Metrics
ALBT Profitability Ratios
ALBT Balance Sheet & Liquidity
ALBT 5-Year Financial Trend
5-Year Trend Summary: Avalon GloboCare Corp.'s revenue has declined by 14% over the 5-year period, indicating business contraction. The most recent EPS of $-23.80 indicates the company is currently unprofitable.
ALBT Growth Metrics (YoY)
ALBT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $345.2K | -$254.3K | $-0.06 |
| Q2 2025 | $327.9K | -$2.1M | $-2.85 |
| Q1 2025 | $314.6K | -$1.4M | $-1.43 |
| Q3 2024 | $331.3K | -$1.5M | $-1.82 |
| Q2 2024 | $306.9K | -$2.1M | $-0.19 |
| Q1 2024 | $296.2K | -$1.4M | $-0.12 |
| Q3 2023 | $317.4K | -$1.5M | $-0.14 |
| Q2 2023 | $290.8K | -$2.0M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ALBT Capital Allocation
ALBT SEC Filings
Access official SEC EDGAR filings for Avalon GloboCare Corp. (CIK: 0001630212)